Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer
A 48-Month Extension to the Randomized, Double-blind, Placebo-Controlled Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer
Sponsor: Roll International Corporation
A PHASE2 clinical study on Prostate Cancer, this trial is ongoing. The trial is conducted by Roll International Corporation and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Roll International Corporation
For direct contact, visit the study record on ClinicalTrials.gov .